OleanderCamargo Pharmaceutical Services, LLC offers support to Phoenix Biotechnology Inc. in the development of PBI-05204, for the treatment of various tropical diseases eligible to receive priority review vouchers. Posted on February 2020June 2022 by Carlos Torres 06 Feb Phoenix Biotechnology has entered the Patents For Humanity awards competition sponsored by the United States Patent & Trademark Office. A recent 2020 publication has shown that oleandrin effectively and selectively targets human breast cancer cells without affecting normal breast epithelial cells. The selectivity is based in part on the relative content of Na,K-ATPase alpha-3 subunit as previously shown by Phoenix Biotechnology scientists.
